Apellis Pharmaceuticals (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). As … Continued
The post Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study appeared first on Investing News Network.